RecruitingPhase 2NCT05025098

Precision Therapy Versus Standard Therapy in AML and MDS in Elderly

Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Akershus
Principal Investigator
Anders Erik Astrup Dahm, MD, PHD
Akershus universitetssykehus
Intervention
Standard therapy(drug)
Enrollment
36 enrolled
Eligibility
60 years · All sexes
Timeline
20212027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05025098 on ClinicalTrials.gov

Other trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Additional recruiting or active studies for the same condition.

See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

← Back to all trials